Beyond CD19 CAR-T cells in lymphoma

Leung, Wingchi K.; Ayanambakkam, Adanma; Heslop, Helen E.; Hill, LaQuisa

doi:10.1016/j.coi.2021.09.009

Cited by 5 publications

(3 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At this point, however, there is no reproducible means to identify patients with lupus responsive to CD19 CAR-T versus those who might require BCMA targeting alone or in combination with CD19 CAR-T therapy. Indeed, there is debate concerning whether CD19 is the most appropriate B cell target, with CD20 and CD22 also being considered 29. Evidence in B cell malignancies suggests that CD20 CAR-T might result in better survival in DLBCL than CD19 CAR-T and even be effective in those relapsing after CD19 CAR-T therapy 19.…”

Section: Optimising Car-t Cell Therapy For Autoimmune Disease Treatmentmentioning

confidence: 99%

Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease

Daamen,

Lipsky

2024

Ann Rheum Dis

View full text Add to dashboard Cite

Chimeric antigen receptors (CARs) are synthetic proteins designed to direct an immune response toward a specific target and have been used in immunotherapeutic applications through the adoptive transfer of T cells genetically engineered to express CARs. This technology received early attention in oncology with particular success in treatment of B cell malignancies leading to the launch of numerous successful clinical trials and the US Food and Drug Administration approval of several CAR-T-based therapies. Many CAR-T constructs have been employed, but have always been administered following a lymphodepletion regimen. The success of CAR-T cell treatment in targeting malignant B cells has led many to consider the potential for using these regimens to delete pathogenic B cells in autoimmune diseases. Preliminary results have suggested efficacy, but the sample size remains small, controlled trials have not been done, the role of immunodepletion has not been established, the most effective CAR-T constructs have not been identified and the most appropriate patient subsets for treatment have not been established.

show abstract

Section: Optimising Car-t Cell Therapy For Autoimmune Disease Treatmentmentioning

confidence: 99%

Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease

Daamen,

Lipsky

2024

Ann Rheum Dis

View full text Add to dashboard Cite

show abstract

“…Chimeric antigen receptor (CAR)–modified T cells are now widely used as anticancer agents, particularly for the treatment of CD19 + malignancies, 1 , 2 and numerous laboratories are exploring new disease targets and interrogating the therapeutic utility of CAR T cells in a range of hematologic and solid tumors. 3 , 4 , 5 , 6 Before clinical translation, these novel therapies must undergo extensive in vitro (two-dimensional [2D] and 3D) and in vivo (animal model) testing, not only to gauge their potency, specificity, and potential efficacy but also to assess the safety of such novel effector molecules.…”

Section: Introductionmentioning

confidence: 99%

A dual-luciferase bioluminescence system for the assessment of cellular therapies

Torres Chavez,

McKenna,

Balasubramanian

et al. 2024

Molecular Therapy: Oncology

View full text Add to dashboard Cite

“…In recent years, there has been more and more basic research and clinical research related to CAR-T cells and more papers. Many scholars have reviewed this therapy from many aspects, including how to improve the efficacy and safety of CAR-T cells (22)(23)(24), the mechanism and management of related toxic reactions (25)(26)(27)(28), the improvement and optimization of CAR structure (29,30), the selection of targets (31,32), the influence of TME on CAR-T cells (33,34), and the research of CAR-T cells in hematological malignancies or solid tumors (35)(36)(37)(38).…”

Section: Introductionmentioning

confidence: 99%

A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021

Miao

Zhang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

ObjectivesA bibliometric and knowledge-map analysis is used to explore hotspots’ evolution and development trends in the CAR-T cell field. By looking for research hotspots and new topics, we can provide new clues and ideas for researchers in this field.MethodsThe articles and reviews regarding CAR-T cells were retrieved and obtained from the Web of Science Core Collection (WOSCC) on October 28th, 2021. CtieSpace [version 5.8.R3 (64-bit)] and VOSviewer (version 1.6.17) were used to conduct the bibliometric and knowledge-map analysis.Results660 authors from 488 institutions in 104 countries/regions published 6,867 papers in 1,212 academic journals. The United States was absolutely in the leading position in this research field. The institution that contributed the most publications was the University of Pennsylvania. Carl H June published the most articles, while Shannon L Maude had the most co-citations. However, there was little cooperation between countries. After 2012, cooperation among various institutions was also small. The journals that published the most CAR-T cell-related papers were Frontiers in immunology and Cancers. Nevertheless, Blood and The New England Journal of Medicine were the most commonly co-cited journals. The most influential research hotspots were the research of CAR-T cells in hematological malignancies, the related research of cytokine release syndrome (CRS), CD19, and the anti-tumor activity and efficacy of CAR-T cells. The latest hotspots and topics included the study of CAR-T cells in solid tumors, universal CAR-T cells, CAR-NK cells, CD22, and anakinra (the IL-1 receptor antagonist). The research of CAR-T cells in solid tumors was a rapidly developing hot field. Emerging topics in this field mainly included the study of CAR-T cells in glioblastoma (related targets: IL13Rα2, EGFRvIII, and HER2), neuroblastoma (related target: GD2), sarcoma (related target: HER2), and pancreatic cancer (related target: mesothelin), especially glioblastoma.ConclusionAs an anti-tumor therapy with great potential and clinical application prospects, CAR-T cell therapy is still in a stage of rapid development. The related field of CAR-T cells will remain a research hotspot in the future.

show abstract

Beyond CD19 CAR-T cells in lymphoma

Cited by 5 publications

References 52 publications

Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease

Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease

A dual-luciferase bioluminescence system for the assessment of cellular therapies

A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021

Contact Info

Product

Resources

About